La supresión hormonal asociada a la menopausia se asocia a un aumento del riesgo cardiovascular, principalmente relacionado con alteraciones del perfil lipídico y metabolismo hidrocarbonado. Inicialmente la terapia hormonal sustitutiva parecía asociarse a una disminución de complicaciones coronarias, si bien estudios controlados más recientes no confirman este beneficio e incluso sugieren aumentar el riesgo coronario y de otras complicaciones trombóticas, así como cáncer de mama. El raloxifeno se presenta como una alternativa al modular selectivamente los receptores estrogénicos antagonizando sus efectos deletéreos en mama y útero, potenciando sus efectos beneficiosos óseos y cardiovasculares. Los primeros datos sugieren que mejora el pronóstico en mujeres de riesgo cardiovascular alto en torno al 40%, si bien son necesarios más estudios que confirmen el posible efecto beneficioso del raloxifeno.
Información de la revista
Vol. 30. Núm. 8.
Páginas 391-396 (septiembre 2004)
Vol. 30. Núm. 8.
Páginas 391-396 (septiembre 2004)
Acceso a texto completo
Tratamiento hormonal sustitutivo en la prevención de cardiopatía isquémica en la menopausia
Visitas
4740
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.J. Lerner, W.B. Kannel.
Patterns of coronary heart disease in women: Perpective from the Framingham Study.
Am Heart J, 114 (1987), pp. 413-414
[2.]
The Writing Group for the PEPI Trial:.
Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women.
JAMA, 273 (1995), pp. 199-208
[3.]
H. Tunsdall-Pedoe.
Mito y paradoja del riesgo coronario y la menopausia.
The Lancet (ed esp), 351 (1998), pp. 1425-1427
[4.]
J.B. McKinlay.
Some contributions from the Social System to the Gender Inequalities in Herat Disease.
J Health Soc Behav, 37 (1996), pp. 1-26
[5.]
S. Hulley, D. Grady, T. Bus, C. Furberg, D. Herrington, B. Riggs, et al.
Randomized trial on estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
JAMA, 280 (1998), pp. 605-613
[6.]
R.K. Ross, A. Paganini-Hill, T.M. Mack, et al.
Menopausal estrogen therapy and protection from death from ischemic heart disease.
Lancet, i (1981), pp. 858-860
[7.]
J.M. Sullivan, R. Vander Zwaag, G.F. Lemp, et al.
Postmenpausal estrogen use and coronary atherosclerosis.
Ann Intern Med, 108 (1988), pp. 358-363
[8.]
H.W. Gruchow, A.J. Anderson, J.J. Barboriak, et al.
Postmenopausal use of estrogen and occlusion of coronary arteries.
Am Heart J, 115 (1985), pp. 954-963
[9.]
M.J. Stampfer, W.C. Willet, G.A. Colditz, et al.
A prospective study of postmenopausal estrogen therapy and coronary heart disease.
N Engl J Med, 313 (1985), pp. 1044-1049
[10.]
M. Falkeborn, I. Persson, A. Terens, et al.
Hormone replacement therapy and the risk of stroke.
Arch Intern Med, 153 (1993), pp. 1201-1209
[11.]
M.J. Stampfer, G.A. Colditz.
Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence.
Prev Med, 20 (1991), pp. 47-63
[12.]
S. Clarke, J. Kelleher, H. Lloyd-Jones, L. Sharples, M. Slack, P.M. Schofield.
Transdermal hormona replacement therapy for secondary prevention of coronary artery disease in postmenopausal women [abstract].
Eur Heart J, 21 (2000), pp. 212
[13.]
P. Angerer, S. Stork, W. Kothny, P. Schmitt, C. von Schacky.
Effect of oral postmenopausal hormona replacement on progresión of atherosclerosis: a randomized, controlled trial.
Arterioscle Thromb Vasc Biol, 21 (2001), pp. 262-268
[14.]
H.N. Hodis, W.J. Mack, R.A. Lobo, D. Shoupe, A. Sevanian, P.R. Mahrer, et al.
Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med, 135 (2001), pp. 939-953
[15.]
D. Grady, D. Herrington, V. Bittner, R. Blumenthal, M. Davidson, M. Hlathy, et al.
Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
JAMA, 288 (2002), pp. 49-57
[16.]
Writing Group for the Women's Health Initiative Investigators..
Risks and benefits of estrogen plus progestin in healthy postmenopausal women.
JAMA, 288 (2002), pp. 321-333
[17.]
J. Hippisley, M. Pringle, N. Crown, C. Coupland.
A case-control study on the effect of hormone replacement therapy on isquemic heart disease.
Br J Gen Pract, 53 (2003), pp. 191-196
[18.]
L. Mosca, P. Collins, D.M. Herrington, et al.
Hormona replacement therapy and cardiovascular disease: a statement for health professionals from the American Heart Association.
Circulation, 104 (2001), pp. 499-503
[19.]
R. Eastell, J. Adachi, K. Harper, et al.
The effects of Raloxifeno on incident vertebral fractures in Postmenopausal women with osteoporosis: 4 years results from the MORE trial.
J Bone Mineral Research, 15 (2000), pp. S229
[20.]
B. Ettinger, D.M. Black, B.H. Mitlak, et al.
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifeno:results from a 3 years randomised clinical trial.
JAMA, 282 (1999), pp. 637-664
[21.]
B.W. Walsh, L.H. Kuller, R.A. Wild, S. Paul, M. Farmer, J.B. Lawrence, et al.
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
JAMA, 279 (1998), pp. 1445-1451
[22.]
E. Barrett-Connor, D. Grady, A. Sashegyi, P.W. Anderson, D.Z. Cox, K. Hoszowski, et al.
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
JAMA, 287 (2002), pp. 847-857
[23.]
S. Yusuf, S. Anand.
Hormone replacement therapy: a time for pause.
CAMJ, 167 (2002), pp. 357-359
[24.]
J. Rymer, R. Wilson, K. Ballard.
Making decisions about hormone replacement therapy.
BMJ, 326 (2003), pp. 322-326
[25.]
W.C. Willet, G. Colditz, M. Stampfer.
Postmenopausal estrogensoppsed, unpposed, or none of the above.
JAMA, 283 (2000), pp. 534-535
[26.]
F.R. Pérez-López.
Tratamiento hormonal de la menopausia: controversias, precisiones y perspectivas.
Med Clin (Barc), 120 (2003), pp. 148-155
[27.]
F. Grodstein, T.B. Clarkson, J.E. Manson.
Understanding the divergent data on postmenopausal hormone therapy.
N Engl J Med, 348 (2003), pp. 645-650
[28.]
A. Day.
Lessons from the Women's Health Initiative: primary preventin and gender health.
CAMJ, 167 (2002), pp. 361-362
Copyright © 2004. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)